Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Holtzman
Washington University, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
C2N Therapeutics
Other : Licensing through the awardee institution
Based on Washington University’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, Washington University determined Dr. Holtzman’s personal financial relationship with C2N, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• Dr. Holtzman’s personal financial relationship is directly related to the research because the research is evaluating a technology developed by Dr. Holtzman which is licensed to C2N and sublicensed to Abbvie.
• Since Dr. Holtzman owns equity in the company, he could directly benefit should the company’s equity value increase as a result of this study.
• Since Dr. Holtzman will earn royalties from the sale and distribution of the licensed and sublicensed technology, he could directly benefit should the study impact the value of the intellectual property.
• Dr. Holtzman’s role as described below could directly affect the research
While the committees determined financial conflicts of interest exist, they concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• The research is basic in nature and in its early stages
• The CIRC understands the emphasis of the research is preclinical (animal studies) and does not focus on the humanized tau antibodies, which have been sublicensed to AbbVie. Thus, the research is unlikely to directly affect the royalties related to the licensed IP or have an impact on the continued development of the humanized antibodies conducted by (b)(4).
• Additionally, a plan has been developed to mitigate the financial conflict of interest.
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy
Project Narrative Alzheimer?s disease is a tauopathy that remains the leading cause of dementia worldwide with no disease-modified treatments currently available, however an emerging therapeutic approach is anti-tau immunotherapies. While conventional immunotherapies are promising, they are limited to targeting extracellular proteins whereas the majority of pathological tau remain in the cytosol of cells. Therefore, we hypothesize targeting intracellular tau might be more efficacious in preventing tauopathy by engineering anti-tau intrabodies that contain distinct tags that shuttle tau to either the proteasome, lysosome or chaperone-mediated autophagy for degradation.
Filed on August 02, 2019.
Tell us what you know about David Holtzman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Holtzman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly | $0 - $4,999 |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Therapeutics | $20,000 - $39,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | $20,000 - $39,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | $10,000 - $19,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly and Company | $0 - $4,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.